Thailand Pharmaceuticals & Healthcare Report Q4 2013 - New Study Released
Thailand's status as a priority watch list country in the Pharmaceutical Research and Manufacturers of America (PhRMA)'s submission to the Special 301 Report is unsurprising. The compulsory licences issued by Thailand in 2011 are still in place, negatively affecting its reputation for intellectual property (IP) protection and thus its direct investment potential. We also highlight that Thailand permits parallel imports - which further impacts PhRMA members' revenues in the country.
View full press release